Sex and gender differences in therapy of type 2 diabetes

被引：67
作者：
Kautzky-Willer, Alexandra [1 ,2 ]
Harreiter, Juergen [1 ]
机构：
[1] Med Univ Vienna, Div Endocrinol & Metab, Dept Internal Med 3, Gender Med Unit, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Gender Med Inst, Gars Am Kamp, Austria
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2017年 / 131卷
关键词：
Sex; Gender; Type; 2; diabetes; Glucose-lowering drugs; Multifactorial therapy; CORONARY-HEART-DISEASE; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; TESTOSTERONE REPLACEMENT THERAPY; STATIN THERAPY; CARDIOVASCULAR-DISEASE; RISK-FACTORS; GLYCEMIC CONTROL; LIFE-STYLE; POSTMENOPAUSAL WOMEN; GLUCOSE-HOMEOSTASIS;
D O I：
10.1016/j.diabres.2017.07.012
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinical guidelines for the management of type 2 diabetes recommend individual therapy considering age, duration of disease, presence of complication and risk of hypoglycaemia. However, at present, the patient's sex has no impact on clinical decisions. Yet, there is mounting data pointing at biological and psychosocial differences between men and women with great impact on progression of disease and complications. Moreover, choices and preferences of therapeutic strategies as well as adherence to lifestyle and pharmacological interventions differ in both sexes. In addition, drug therapy may have sex-specific side effects. Therefore, there is need of more research on biological differences and of evidence-based individualised targeted sex-sensitive therapeutic concepts. Clinical guidelines must consider relevant sex-differences. Development and implementation of sex-specific programs may help to improve adherence to therapy and to reduce progression of disease and development of complications. A more gender-sensitive clinical approach may improve quality of life and increase health and life expectancy in men and women with type 2 diabetes. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码：230 / 241
页数：12
相关论文
共 109 条
[1]   Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study [J].
Alperovitch, Annick ;
Kurth, Tobias ;
Bertrand, Marion ;
Ancelin, Marie-Laure ;
Helmer, Catherine ;
Debette, Stephanie ;
Tzourio, Christophe .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350 :h2335
[2]   8. Cardiovascular Disease and Risk Management [J].
不详 .
DIABETES CARE, 2016, 39 :S60-S71
[3]  
American Diabetes Association, 2017, Diabetes Care, V40, pS114
[4]   Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus [J].
Andersson, B ;
Mattsson, LA ;
Hahn, L ;
Marin, P ;
Lapidus, L ;
Holm, G ;
Bengtsson, BA ;
Bjorntorp, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :638-643
[5]  
[Anonymous], 2016, N ENGL J MED
[6]  
[Anonymous], 2013, MAT SOCIOMED
[7]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[8]  
Balhara Yatan Pal Singh, 2015, Indian J Endocrinol Metab, V19, P451, DOI 10.4103/2230-8210.159023
[9]   Sex differences in platelet reactivity and response to low-dose aspirin therapy [J].
Becker, DM ;
Segal, J ;
Vaidya, D ;
Yanek, LR ;
Herrera-Galeano, JE ;
Bray, PF ;
Moy, TF ;
Becker, LC ;
Faraday, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (12) :1420-1427
[10]   Understanding Disparities in Lipid Management Among Patients with Type 2 Diabetes: Gender Differences in Medication Nonadherence after Treatment Intensification [J].
Billimek, John ;
Malik, Shaista ;
Sorkin, Dara H. ;
Schmalbach, Priel ;
Quyen Ngo-Metzger ;
Greenfield, Sheldon ;
Kaplan, Sherrie H. .
WOMENS HEALTH ISSUES, 2015, 25 (01) :6-12
12345678910